Introduction
============

Catheter-related bloodstream infections (CRBSIs) due to pathogenic microorganisms are healthcare-associated infections that result in systemic complications and have a profound effect on patient prognosis [@B1]-[@B6]. Removal of the intravenous catheter is effective when a CRBSI occurs in a patient undergoing treatment with a nutrition solution [@B7]. However, repeated removal and catheterization of central venous catheters (CVCs) and totally implantable central venous access devices (CVADs) in elderly patients or patients who require long-term parenteral nutrition (PN) therapy make it difficult to maintain access vessels to the central venous system and reduce the patient\'s quality of life. Ethanol lock therapy and antimicrobial lock therapy have been used to fight against CRBSIs in addition to catheter removal [@B8]-[@B13]. However, the evidence and scientific basis for ethanol lock therapy are currently insufficient [@B7], [@B14] and antimicrobial lock therapy is not recommended by the Centers for Disease Control and Prevention because it may cause the pathogenic microorganisms to acquire resistance [@B15]. On the other hand, it has been reported that taurolidine, a substance with antibacterial activity, is effective in preventing the occurrence of CRBSIs [@B16], [@B17]. The European Society for Clinical Nutrition and Metabolism guidelines on home parenteral nutrition recommend taurolidine lock solution as an additional strategy to prevent CRBSIs (Grade of Recommendation B) [@B18]. Additives or pH adjustments in pharmaceuticals or foods affect the survival of microbial pathogens. Ascorbic acid, which is widely used as a food additive and a drug, has a bactericidal effect due to the generation of reactive oxygen species resulting from the Fenton reaction [@B19], [@B20]. Citric acid is also added to pharmaceuticals and foods as a pH adjuster. However, citric acid has strong acidity and antibacterial activity due to the release of hydrogen ions, which inhibit the metabolism of microorganisms [@B21]. In addition, sodium bisulfite exerts a strong bactericidal action by inhibiting ATP synthesis and bacterial metabolism [@B22]-[@B24]. Sodium bisulfite is used as a stabilizing agent or antioxidant in commercially available PN solutions in Japan. Therefore, in a catheter lumen contaminated with a bacterial pathogen, it is possible to sterilize it by passing a highly acidic PN solution rich in a preservative. However, the bactericidal action and growth inhibition effect of PN solutions have not yet been examined. In this study, we focused on Plas-Amino^®^ (PA) as a commercially available PN solution that contains the highest amount of sodium bisulfite as a preservative and the highest acidity in Japan [@B25], and investigated its effect on pathogenic microorganisms colonizing catheter lumen.

Materials and Methods
=====================

Microorganisms employed
-----------------------

Microbial pathogens were selected based on the data from a large-scale multicenter survey carried out by Wisplinghoff et al. [@B1] as well as the CRBSI report in Japan [@B26], [@B27]. Standard American Type Culture Collection (ATCC) strains for all the microorganisms were purchased from Microbiologics, Inc. (St. Cloud, MN, USA):*Staphylococcus aureus* (ATCC6538), *Staphylococcus epidermidis* (ATCC12228), *Bacillus cereus* (ATCC11778), *Serratia marcescens* (ATCC13880), *Pseudomonas aeruginosa* (ATCC9027), and *Candida albicans* (ATCC10231).

Test solutions
--------------

BFLUID^®^ (BF), a commercial peripheral parenteral nutrition (PPN) solution containing glucose, electrolytes, and amino acids, was purchased from Otsuka Pharmaceutical Factory, Inc. (Tokushima, Japan). Otsuka MV Injection^®^ (MVs), a commercial multivitamin preparation containing both water-soluble vitamins (vitamins B~1~, B~2~, B~6~, B~12~, and C, folic acid, nicotinamide, biotin, and panthenol) and water-insoluble vitamins (vitamins A, D, E, and K), was purchased from Otsuka Pharmaceutical Factory, Inc. In addition, PA, also purchased from Otsuka Pharmaceutical Factory, Inc., was used as a nutrition solution formulation that possibly has an antimicrobial activity. PA is a highly acidic (pH 4.6) solution that contains a higher concentration of sodium bisulfite (0.5 g/L) as a preservative than that in the other nutrition solutions [@B25]. Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} show the compositions of BF, PA, and MVs. In order to create a catheter lumen microorganism contamination model in this experiment, a test solution suitable for bacterial colonization and growth was prepared by adding MVs to 1,000 mL of BF (BF-MVs).

Preparation of the catheter lumen microorganism contamination model, incubation, and sampling
---------------------------------------------------------------------------------------------

One platinum loop from each strain was suspended and diluted in a physiological saline (Otsuka Pharmaceutical Factory, Inc.) to obtain a constant concentration of each pathogenic microorganism solution. Then, 5 mL of each solution was injected into a PLANECTA Infusion Set^®^ (JMS, Inc., Tokyo, Japan) and a TOP Extension Tube^®^ (TOP, Inc., Tokyo, Japan) connected to BF-MVs, and solution flow was blocked for 1 h. BF-MVs was added dropwise at a constant rate of 40 mL/h to remove any microorganisms that did not colonize the catheter lumen.

Droplet samples (10-20 mL) were collected at 24 h after the addition of each bacterial pathogen. After sampling, we continued adding BF-MVs dropwise in the control group and replaced BF-MVs with PA in the test group for 18 h (40 mL/h). We selected 18 h because our preliminary examination showed that sterilization requires more than 12 h *in vitro* (Table [1](#T1){ref-type="table"}S). Thereafter, PA was replaced with BF-MVs and added again dropwise. One aliquot (10-20 mL) of each test solution was sampled at 48 and 72 h. All experiments were performed three times at 25 °C. Figure [1](#F1){ref-type="fig"} shows a schematic diagram of the experimental procedure.

Measurement of microbial colony
-------------------------------

All sampled test solutions were assessed using the membrane filter method in the presence of a small number of microorganisms. All aliquots (10-20 mL) were filtered using a 0.45 µm nitrocellulose membrane filter (ADVANTEC Co., Ltd., Tokyo, Japan) to perform a sterility test as described by the Japanese Pharmacopoeia [@B28], and then each filter was placed on a soybean-casein digest (SCD) agar medium. When necessary, any test solution sampled was serially diluted with a physiological saline before inoculation. The number of microbial pathogen colony-forming units (CFUs) on each SCD agar medium was counted after 24 h of incubation at 37 °C, and the value of CFUs/mL was calculated using the number of CFUs per SCD agar medium, the inoculum dose, and the dilution ratio. Results are represented as CFUs/mL values in semilogarithmic graphs. It has previously been shown that the biological significance of bacterial growth can be evaluated without performing any statistical analyses; hence, no statistical analyses were performed for the obtained data [@B29]-[@B32].

Results
=======

In the control group (with only BF-MVs), the standard strain of *S. aureus* (ATCC6538) colonized and grew in the catheter lumen treated with BF-MVs at 24 h and rapidly increased at 48 and 72 h. In addition, *S. aureus* proliferated from 9.3 × 10^2^ CFUs/mL to 9.7 × 10^5^ CFUs/mL after 48 h and reached 3.1 × 10^7^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}A). The standard strain of *B. cereus* (ATCC11778) significantly colonized and grew in the catheter lumen treated with BF-MVs at 24 h and rapidly increased at 48 and 72 h. Moreover, *B. cereus* proliferated from 7.1 × 10^5^ CFUs/mL to 2.0 × 10^7^ CFUs/mL after 48 h and reached 3.3 × 10^9^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}C). However, the standard strain of *S. epidermidis* (ATCC12228) hardly colonized and grew in the catheter lumen treated with BF-MVs at 24 h and increased slowly at 48 and 72 h. Moreover, *S. epidermidis* proliferated from 2.0 × 10^0^ CFUs/mL to 1.8 × 10^1^ CFUs/mL after 48 h and to 1.4 × 10^3^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}B). The standard strain of *S. marcescens* (ATCC13880) slightly colonized and grew in the catheter lumen treated with BF-MVs at 24 h and increased significantly at 48 and 72 h. In addition, *S. marcescens* proliferated from 1.7 × 10^1^ CFUs/mL to 4.4 × 10^4^ CFUs/mL after 48 h and to 1.7 × 10^6^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}D). The standard strain of *P. aeruginosa* (ATCC9027) also slightly colonized and grew in the catheter lumen treated with BF-MVs at 24 h and increased slowly at 48 and 72 h. In addition, *P. aeruginosa* proliferated from 4.3 × 10^1^ CFUs/mL to 1.0 × 10^3^ CFUs/mL after 48 h and to 9.4 × 10^3^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}E). On the other hand, no pathogenic microbes were detected after 48 and 72 h in the PA group, and it was concluded that PA has a bactericidal effect on all the pathogenic bacteria used (Figs. [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}E). Furthermore, the standard strain of *C. albicans* (ATCC10231) colonized and grew in the catheter lumen treated with BF-MVs at 24 h and rapidly increased at 48 and 72 h. In addition, *C. albicans* proliferated from 1.7 × 10^2^ CFUs/mL to 3.2 × 10^3^ CFUs/mL after 48 h and to 1.1 × 10^6^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}F). Although no bactericidal effect was observed on the *C. albicans* fungus in the PA group, the addition of PA dropwise had a significant growth inhibition effect on *C. albicans* in comparison with the control group. The growth of *C. albicans* was inhibited from 2.0 × 10^2^ CFUs/mL to 1.3 × 10^3^ CFUs/mL after 48 h and to 3.7 × 10^3^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}F).

We next performed additional experiments on *C. albicans*. A schematic diagram of the experimental procedure is shown in Figure [1](#F1){ref-type="fig"}S. In the first 24 h, the standard strain of *C. albicans* (ATCC10231) colonized and grew in the catheter lumen in a similar way to BF-MVs. Although no bactericidal action was observed, the intermittent administration of PA exerted a potent antiproliferative effect against *C. albicans*. The growth of *C. albicans* was inhibited from 9.0 × 10^1^ CFUs/mL to 1.8 × 10^1^ CFUs/mL after 48 h and to 2.3 × 10^2^ CFUs/mL after 72 h (Figure [2](#F2){ref-type="fig"}S).

Discussion
==========

Nutrients required for growth differ depending on the bacterial species, and there have been reports on the growth characteristics of bacteria in commercially available PPN and total parenteral nutrition (TPN) solutions [@B33]-[@B36]. We have previously demonstrated that *C. albicans* do not grow in commercial PPN solutions but rather grow significantly in PPN solutions with biotin [@B37]. However, much is still unknown about the relationship between bacterial growth and nutritional factors. Moreover, pH and osmotic pressure, in addition to nutrients, are important factors in the growth of bacteria. It has been shown that using a PPN solution with a high pH value and low osmolarity is more suitable for microbial growth than using a TPN solution with a low pH value and high osmolarity [@B38]. Commercially available PN solutions contain various nutrients, making them suitable media for bacterial growth [@B2], [@B35].

We herein attempted to create a catheter lumen microorganism contamination model using typical CRBSI-causing pathogens. We added multivitamins to commercially available PPN solutions and prepared solutions (BF-MVs) more suitable for bacterial growth. When all pathogenic microorganism solutions were injected into the catheter and the flow pass was blocked for 1 h, all bacteria showed colonization and growth in the catheter lumen (Figure [2](#F2){ref-type="fig"}). Thus, we established a method for constructing a catheter lumen microorganism contamination model. In particular, *B. cereus* was found to colonize and proliferate significantly in the catheter lumen (Figure [2](#F2){ref-type="fig"}C) and to float in the air or adhere to the fingers while handling linen [@B26], [@B39]. After handling linen, treatment with nutrition solutions should be avoided. Moreover, *S. aureus* were found to exhibit remarkable colonization and proliferation in the catheter lumen similar to those of *B. cereus* (Figure [2](#F2){ref-type="fig"}A). Shiraishi et al. reported that *S. aureus* grow in TPN solutions containing lipid emulsions [@B33]. In addition, it has been reported that *S. aureus* require nicotinamide [@B36]. It was also found that *S. epidermidis* and *P. aeruginosa* hardly colonize in the catheter lumen and grow slowly after 48 and 72 h (Figs. [2](#F2){ref-type="fig"}B and [2](#F2){ref-type="fig"}E). Generally, *P. aeruginosa* are resistant to a wide range of antibiotics and often cause opportunistic infections. In addition, *S. epidermidis* are considered to be the most frequently identified Gram-positive cocci and are a causative agent of CRBSIs [@B1]. Therefore, unlike what we expected, we considered the colonization and proliferation of *S. epidermidis* in the catheter lumen to be the highest (Figure [2](#F2){ref-type="fig"}B), a result that is in fact very interesting. *S. epidermidis* are considered to be indigenous bacteria of the epidermis, which can enter the blood vessels during an injection and cause a BSI while using blood as a source of nutrition. It was also found that *S. marcescens* slightly colonize and proliferate in the catheter lumen and increase significantly at 48 and 72 h (Figure [2](#F2){ref-type="fig"}D). Omotani et al. reported that *S. marcescens* grow well in PPN solutions, which are less nutritious than TPN solutions [@B36]. In addition, it was found that *C. albicans* proliferates rapidly 48 and 72 h after colonization in the catheter lumen (Figure [2](#F2){ref-type="fig"}F). Generally, CRBSIs caused by *C. albicans* are known to have a high mortality rate, and attention must be paid to the loss of vision that might probably occur because of fungal endophthalmitis [@B5], [@B40]. CRBSIs are mainly caused by bacterial pathogens adhering to the catheter connection, outer circumference, and lumen during solution preparation, catheter insertion, and solution exchange [@B41]. Our data indicate that pathogenic microorganisms can use nutrition solutions to grow when they colonize a catheter lumen. Therefore, a catheter lumen microorganism contamination model may be a useful tool to elucidate the mechanisms of CRBSIs and study how to prevent pathogenic bacterial contamination.

In this study, we investigated the effects of PA on pathogenic bacteria colonizing catheter lumens to prevent the occurrence of CRBSIs. After flowing PA into the catheter lumen contaminated with each bacterium for 18 h, PA was switched to BF-MVs and aliquots were collected 48 and 72 h later. None of the microorganisms was detected in the samples. Therefore, we concluded that PA has a bactericidal effect on *S. aureus*, *S. epidermidis*, *B. cereus*, *S. marcescens*, and *P. aeruginosa* (Figs. [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}E), and we confirmed that it has an antiproliferative effect on *C. albicans* (Figure [2](#F2){ref-type="fig"}F). In addition to chitin, *C. albicans* have a strong cell wall consisting of β-D-glucan, which promotes their survival and growth under hyperosmotic and acidic conditions, such as TPN solutions, in comparison to CRBSI-causing bacteria [@B34], [@B37]. Hence, it was suggested that the penetration of sodium bisulfite contained in PA into the cells was partially blocked and that no bactericidal effect could be obtained. Among all the commercially available PPN solutions in Japan, PA is known to contain the highest concentration of sodium bisulfite (0.5 g/L) as a preservative [@B25]. Sodium bisulfite (NaHSO~3~), which mainly exists in the form of sulfurous acid (SO~2~ or H~2~SO~3~) in its molecular form with a low pH [@B23], [@B42], [@B43], is a widely used preservative in pharmaceuticals and foods, which has antioxidative and antibacterial effects. This molecular form has the ability to permeate the cells and inhibit the ATP synthesis and metabolism of bacteria [@B22]-[@B24]. Therefore, we considered PA to be highly acidic, to exhibit an increased abundance of molecular forms, and to have bactericidal and antiproliferative effects on pathogenic microorganisms. We also revealed that PA has bactericidal and antiproliferative effects on pathogenic microorganisms in catheter lumens. The limitations of this experimental model are that the treatment duration of PA was 18 h in all experiments and that we did not observe the growth trend of *C. albicans* after 72 h. Although PA is an infusion formulation that does not contain vitamins, it suffices as an energy source for the growth and development of bacterial pathogens because it mainly consists of glucose, amino acids and electrolytes. Hence, if no bacterial pathogens are detected after PA treatment, it can be concluded that the bactericidal effect observed is due to the low pH of and/or sodium bisulfite contained in PA. In this study, we found that PA remarkably suppressed the growth of *C. albicans* and demonstrated a clear bactericidal effect against bacterial pathogens other than fungi. Intermittent administration of PA against *C. albicans* may have a certain effect on the prevention of CRBSIs in cases where removing the CVC from the patient is difficult. Although catheter removal is effective in CRBSI, repeated removal and insertion can result in the loss of the catheter insertion path as a result of obstruction of the access vessel. Furthermore, implantation of totally implantable CVADs carries the risk of serious mechanical complications, such as air embolisms, arterial puncture, and pneumothorax. Intermittent administration of PA might be effective in preventing CRBSIs in cases where catheter removal from the patients is difficult. In the future, it is expected that solutions with an antimicrobial effect, such as PA, will help control CRBSIs, and we also hope that our research results prove helpful in the suppression of CRBSIs.

Conclusion
==========

This study shows that highly acidic parenteral nutrition (PN) solutions containing a high concentration of sodium bisulfite have bactericidal and antiproliferative effects. It was also found that Plas-Amino^®^ (PA) can be used as a peripheral parenteral nutrition (PPN) solution, which has a low risk of allergic reactions and side effects in patients. If a central venous catheter (CVC) or totally implantable CVAD becomes contaminated, it is possible to use PA to sterilize the catheter lumen and suppress bacterial growth without removing the catheter or the device. Component analysis of solutions that have secondary effects, such as PA, can help develop new lock therapy alternatives to ethanol lock therapy and antimicrobial lock therapy.
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![Experimental procedure, first experiment for all bacterial pathogens. In the control group, BFLUID^®^ (BF) with Otsuka MV Injection^®^ (MVs, BF-MVs) was added dropwise for 72 h. In the test group, BF-MVs was added dropwise for 24 h, and then Plas-Amino^®^ (PA) was added dropwise for 18 h, followed by the addition of BF-MVs dropwise again for 30 h. Then, after 24, 48, and 72 h, all aliquot samples were collected and the colony-forming unit (CFU)/mL value was measured.](ijmsv17p1833g001){#F1}

![Bactericidal and antiproliferative effects of Plas-Amino^®^ (PA) on pathogenic microorganisms. Droplet samples were collected at 24, 48, and 72 h, and the colony-forming unit (CFU)/mL value was measured. (**A**) Bactericidal effect of PA on *Staphylococcus aureus*. (**B**) Bactericidal effect of PA on *Staphylococcus epidermidis*. (**C**) Bactericidal effect of PA on *Bacillus cereus*. (**D**) Bactericidal effect of PA on *Serratia marcescens*. (**E**) Bactericidal effect of PA on *Pseudomonas aeruginosa*. (**F**) Antiproliferative effect of PA on *Candida albicans*. PA (◆) and BFLUID^®^ (BF) with multivitamins (BF-MVs; ■) were used as the control. All data are represented as the mean ± standard deviation (SD; n=3). n.d.: not detectable.](ijmsv17p1833g002){#F2}

###### 

Composition of BFLUID^®^ (BF) and Plas-Amino^®^ (PA)

  Category                     Component                         BFLUID^®^           Plas-Amino^®^
  ---------------------------- --------------------------------- ------------------- -------------------
  **Composition per 500 mL**                                                         
  Carbohydrate                 Glucose                           37.50 g             37.50 g
  Amino Acids                  L-Leucine                         2.100 g             2.05 g
  L-Isoleucine                 1.200 g                           0.90 g              
  L-Valine                     1.200 g                           1.00 g              
  L-Lysine Hydrochloride       1.965 g                           3.10 g              
  (as L-Lysine)                (1.573 g)                         (2.48 g)            
  L-Threonine                  0.855 g                           0.90 g              
  L-Tryptophan                 0.300 g                           0.29 g              
  L-Methionine                 0.585 g                           1.20 g              
  Acetylcysteine               0.202 g                           \-                  
  (as L-Cysteine)              (0.150 g)                         \-                  
  L-Phenylalanine              1.050 g                           1.45 g              
  L-Tyrosine                   0.075 g                           \-                  
  L-Arginine                   1.575 g                           1.10 g              
  L-Histidine                  0.750 g                           0.50 g              
  L-Alanine                    1.200 g                           \-                  
  L-Proline                    0.750 g                           \-                  
  L-Serine                     0.450 g                           \-                  
  Glycine                      0.855 g                           1.70 g              
  L-Aspartic Acid              0.150 g                           \-                  
  L-Glutamic Acid              0.150 g                           \-                  
  Electrolytes                 Na^+^                             17.5 mEq            17 mEq
  K^+^                         10 mEq                            \-                  
  Mg^2+^                       2.5 mEq                           \-                  
  Ca^2+^                       2.5 mEq                           \-                  
  Cl^-^                        17.5 mEq                          17 mEq              
  SO~4~^2-^                    2.5 mEq                           \-                  
  Acetate^-^                   8 mEq                             \-                  
  L-Lactate^-^                 10 mEq                            \-                  
  Citrate^3-^                  3 mEq                             \-                  
  P                            5 mmol                            \-                  
  Zn                           2.5 μmol                          \-                  
  Vitamin                      Thiamine Chloride Hydrochloride   0.96 mg             \-
  **pH**                                                         Approximately 6.7   Approximately 4.6
  **ORP**                                                        Approximately 3     Approximately 3
  **Additive Agent**           Sodium Bisulfite                  0.05 g/L            0.5 g/L

ORP: osmotic pressure ratio to physiological saline.

###### 

Composition of MVs (Otsuka MV Injection^®^)

  Composition per 4 mL         
  ---------------------------- ---------------
  **Water-Soluble Vitamins**   
  Vitamin B~1~                 3.1 mg
  Vitamin B~2~                 3.6 mg
  Vitamin B~6~                 4.0 mg
  Vitamin B~12~                0.005 mg
  Vitamin C                    100 mg
  Folic Acid                   0.4 mg
  Nicotinamide                 40 mg
  Biotin                       0.06 mg
  Panthenol                    14 mg
  **Fat-Soluble Vitamins**     
  Vitamin A Oil                3300 Vit.A IU
  Vitamin D~3~                 0.005 mg
  Vitamin E                    10 mg
  Vitamin K                    2 mg

Vit.A IU, international unit for vitamin A.
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